STZ - Dividend announcements

ROCHESTER, N.Y., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE:STZ), a leading beverage alcohol company, announced today that on September 30, 2025, its Board of Directors declared a quarterly cash dividend of $1.02 per share of Class A Common Stock payable on November 13, 2025, to stockholders of record as of the close of business on October 30, 2025. ABOUT CONSTELLATION BRANDSConstellation Brands (NYSE:STZ) is a leading international producer and marketer of beer, wine, and spirits with operations in the U.S., Mexico, New Zealand, and Italy. Our mission is to build brands that people love because we believe elevating human connections is Worth Reaching For. It's wor

ROCHESTER, N.Y., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE:STZ), a leading beverage alcohol company, announced today that on January 8, 2025, its Board of Directors declared a quarterly cash dividend of $1.01 per share of Class A Common Stock payable on February 21, 2025, to stockholders of record as of the close of business on February 7, 2025. ABOUT CONSTELLATION BRANDSConstellation Brands (NYSE:STZ) is a leading international producer and marketer of beer, wine, and spirits with operations in the U.S., Mexico, New Zealand, and Italy. Our mission is to build brands that people love because we believe elevating human connections is Worth Reaching For. It's wort

LONDON, Dec. 3, 2020 /PRNewswire/ -- 2021 could be a big year for this soon-to-be $16-trillion biotech opportunity. More importantly, it could be a big year for companies pioneering a new form of therapy that could effectively treat the world's #1 disability. It's a disability that's costing the economy $1 trillion in lost production every single year. In fact, the revolutionary treatment could be at our doorstep by 2021. And the next few months are critical.   Mentioned in today's commentary includes:  Constellation Brands, Inc. (NYSE: STZ), Molson Coors Beverage Company (NYSE: TAP), Altria Group, Inc. (NYSE: MO), GW Pharmaceuticals plc (NASDAQ: GWPH), Curaleaf Holdings, Inc. (OTCQX: CUR